收入
成本
利润
| Item | Category | Value | YoY |
|---|---|---|---|
| Sales | revenue | 16.29B | 4.87% |
| Total costs, expenses and other | cost | 19.82B | 105.90% |
| Research and development | cost | 12.59B | 247.75% |
| Cost of sales | cost | 4.20B | 22.70% |
| Selling, general and administrative | cost | 2.70B | 5.80% |
| Restructuring costs | cost | 195.00M | 182.61% |
| Other segment items | revenue | 138.00M | 294.29% |
| Segment | Value | YoY |
|---|---|---|
| Pharmaceutical segment | 14.35B | 5.21% |
| Animal Health segment | 1.79B | 12.78% |
| Others | 146.00M | -51.82% |
| Segment | Value | YoY |
|---|---|---|
| UNITED STATES | 9.16B | 7.53% |
| EMEA | 3.89B | 12.51% |
| Latin America | 874.00M | 10.35% |
| Asia Pacific | 738.00M | 7.11% |
| Other Countries | 679.00M | -3.14% |
| JAPAN | 555.00M | -17.04% |
| CHINA | 390.00M | -44.44% |
| Item | Category | Value | YoY |
|---|---|---|---|
| Accounts receivable (net of allowance for doubtful accounts of $103 in 2026 and $97 in 2025) | assets | 12.21B | |
| Other current assets | assets | 10.62B | |
| Inventories | assets | 6.48B | |
| Cash and cash equivalents | assets | 5.33B | |
| Short-term investments | assets | 375.00M | |
| Other current assets | assets | 35.02B | |
| Other intangibles, net | assets | 25.75B | |
| Property, plant and equipment, at cost, net of accumulated depreciation of $22,288 in 2026 and $21,914 in 2025 | assets | 25.43B | |
| Goodwill | assets | 21.58B | |
| Other assets | assets | 19.81B | |
| Investments | assets | 1.10B | |
| Total assets | assets | 128.69B | |
| Long-term debt | liabilities | 46.67B | |
| Total equity | liabilities | 45.93B | |
| Total current liabilities | liabilities | 26.95B | |
| Other noncurrent liabilities | liabilities | 7.64B | |
| Deferred income taxes | liabilities | 1.49B | |
| Noncontrolling interests | liabilities | 53.00M | |
| Less treasury stock, at cost: 1,107,410,143 shares in 2026 and 1,102,476,756 shares in 2025 | equity | 63.75B | |
| Total merck & co., inc. stockholders’ equity | equity | 45.88B | |
| Accrued and other current liabilities | liabilities | 14.55B | |
| Income taxes payable | liabilities | 3.95B | |
| Trade accounts payable | liabilities | 3.86B | |
| Loans payable and current portion of long-term debt | liabilities | 2.44B | |
| Dividends payable | liabilities | 2.14B | |
| Accumulated other comprehensive loss | liabilities | 4.06B | |
| Stockholders' equity before deduction for treasury stock | equity | 109.62B | |
| Aggregate | liabilities | 113.69B | |
| Retained earnings | liabilities | 66.72B | |
| Other paid-in capital | liabilities | 45.18B | |
| Common stock, $0.50 par value authorized - 6,500,000,000 shares issued - 3,577,103,522 shares in 2026 and 2025 | liabilities | 1.79B |
| Item | Value |
|---|---|
| Charge for research and development asset acquisition | 8.54B |
| Amortization | 931.00M |
| Depreciation | 581.00M |
| Share-based payment arrangement, noncash expense | 185.00M |
| Other noncash income (expense) | 20.00M |
| Equity securities, fv-ni, gain (loss) | -168.00M |
| Deferred income taxes | -315.00M |
| Adjustment to reconcile net income to cash provided by (used in) operating activity, increase (decrease) in operating capital | -1.61B |
| Net (loss) income | -4.24B |
| Item | Value |
|---|---|
| Payment for (proceeds from) other investing activity | -66.00M |
| Payments to acquire investments | -374.00M |
| Payments to acquire property, plant, and equipment | -991.00M |
| Payments to acquire businesses, net of cash acquired | -8.78B |
| Item | Value |
|---|---|
| Net change in short-term borrowings | 1.06B |
| Proceeds from exercise of stock options | 157.00M |
| Other | -80.00M |
| Payments for repurchase of common stock | -874.00M |
| Repayments of long-term debt | -1.14B |
| Payments of ordinary dividends, common stock | -2.10B |
| Item | Value |
|---|---|
| Cash and cash equivalents, beginning of period | 14.69B |
| Cash and cash equivalents, end of period | 5.40B |
快速穿透 10-K/10-Q 复杂数据。通过利润表及资产负债表桑基图,与现金流量表瀑布图,一站式洞悉企业财务流向。
在左侧搜索公司并选择一份报告。
申请股票支持